Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2CNS 1

Conditions

Urinary Bladder Neoplasms 2

Interventions

Docetaxel 77Radiotherapy 73Prednisone 66Leuprolide 51Goserelin 49Gemcitabine 49Cisplatin 48bicalutamide 46enzalutamide 43Androgen Antagonists 36pembrolizumab 32Abiraterone Acetate 31Mitomycin 29acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28Magnetic Resonance Spectroscopy 28Carboplatin 27Flutamide 25Nivolumab 24Triptorelin Pamoate 23Sunitinib 23apalutamide 22Radiation 22Doxorubicin 20darolutamide 19abiraterone 18Gonadotropin-Releasing Hormone 18cabozantinib 17atezolizumab 16Specimen Handling 16Radiosurgery 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Drug Delivery Systems × Genitourinary × Clear all
NCT06525571 2025-11-18

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Johns Hopkins University

Phase 3 Recruiting
200 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05600322 2024-10-03

Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer

Photocure

Phase 3 Completed
158 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡